J A Kanis

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. pmc Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)
    E Hernlund
    OptumInsight, Stockholm, Sweden
    Arch Osteoporos 8:136. 2013
  2. ncbi request reprint The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 18:1033-46. 2007
  3. ncbi request reprint The use of multiple sites for the diagnosis of osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX Sheffield, UK
    Osteoporos Int 17:527-34. 2006
  4. ncbi request reprint Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 16:15-25. 2005
  5. ncbi request reprint Intervention thresholds for osteoporosis in the UK
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
    Bone 36:22-32. 2005
  6. ncbi request reprint Requirements for DXA for the management of osteoporosis in Europe
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:229-38. 2005
  7. ncbi request reprint Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:1065-70. 2005
  8. ncbi request reprint Alcohol intake as a risk factor for fracture
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:737-42. 2005
  9. ncbi request reprint A meta-analysis of previous fracture and subsequent fracture risk
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Bone 35:375-82. 2004
  10. ncbi request reprint Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK
    Osteoporos Int 15:862-71. 2004

Detail Information

Publications78

  1. pmc Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)
    E Hernlund
    OptumInsight, Stockholm, Sweden
    Arch Osteoporos 8:136. 2013
    ..This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27)...
  2. ncbi request reprint The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 18:1033-46. 2007
    ..The combination of clinical risk factors and BMD provide higher specificity and sensitivity than either alone. INTRODUCTION AND HYPOTHESES: To develop a risk assessment tool based on clinical risk factors (CRFs) with and without BMD...
  3. ncbi request reprint The use of multiple sites for the diagnosis of osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX Sheffield, UK
    Osteoporos Int 17:527-34. 2006
    ..It has been suggested that bone mineral density (BMD) measurements should be made at multiple sites, and that the lowest T-score should be taken for the purpose of diagnosing osteoporosis...
  4. ncbi request reprint Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 16:15-25. 2005
    ..In relation to threshold values that are recommended in the UK, the analysis suggests that raloxifene is cost-effective in the treatment of postmenopausal women at an increased risk of vertebral fractures...
  5. ncbi request reprint Intervention thresholds for osteoporosis in the UK
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
    Bone 36:22-32. 2005
    ....
  6. ncbi request reprint Requirements for DXA for the management of osteoporosis in Europe
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:229-38. 2005
    ..The total direct costs were estimated at 31.7 billion Euros (21.165 billion UK pounds), which were expected to increase to 76.7 billion Euros (51.1 billion UK pounds) in 2050 based on the expected changes in the demography of Europe...
  7. ncbi request reprint Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:1065-70. 2005
    ..The use of absolute risk permits information from different types of bone mineral measurements to be applied for the assessment of patients, either alone or in combination with other independent risk factors...
  8. ncbi request reprint Alcohol intake as a risk factor for fracture
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:737-42. 2005
    ..We conclude that reported intake of alcohol confers a risk of some importance beyond that explained by BMD. The validation of this risk factor on an international basis permits its use in case-finding strategies...
  9. ncbi request reprint A meta-analysis of previous fracture and subsequent fracture risk
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Bone 35:375-82. 2004
    ..Its validation on an international basis permits the use of this risk factor in case finding strategies...
  10. ncbi request reprint Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, S10 2RX, Sheffield, UK
    Osteoporos Int 15:862-71. 2004
    ..5 SD) but without a prior vertebral fracture, treatment exceeded the threshold for cost-effectiveness. However, if an additional, independent risk factor was assumed (e.g., corticosteroid use) treatment became cost-effective...
  11. ncbi request reprint Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden
    John A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:6-14. 2005
    ....
  12. ncbi request reprint Smoking and fracture risk: a meta-analysis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 16:155-62. 2005
    ..Its validation on an international basis permits the use of this risk factor in case finding strategies...
  13. ncbi request reprint Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 19:1395-408. 2008
    ..Assessment and intervention thresholds are developed and proposed in men aged over 50 years and postmenopausal women for the UK based on fracture probability from the WHO fracture risk assessment tool (FRAX)...
  14. ncbi request reprint Approaches to the targeting of treatment for osteoporosis
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Nat Rev Rheumatol 5:425-31. 2009
    ..The tool increases sensitivity without trading specificity, and is now being used in the reappraisal of clinical guidelines...
  15. doi request reprint Partial adherence: a new perspective on health economic assessment in osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 22:2565-73. 2011
    ..This review highlights a number of avenues for further research, such as improved definition of thresholds of compliance and persistence, as well as gap length, offset times, and fraction of benefit...
  16. pmc Towards a diagnostic and therapeutic consensus in male osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
    Osteoporos Int 22:2789-98. 2011
    ..The consensus views on osteoporosis in men are reported...
  17. doi request reprint A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®)
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, South Yorkshire, UK
    Osteoporos Int 22:2347-55. 2011
    ..Hazard ratios for the effect of strontium ranelate on the fracture outcome did not change significantly with increasing fracture probability...
  18. doi request reprint Guidance for the adjustment of FRAX according to the dose of glucocorticoids
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S102RX, UK
    Osteoporos Int 22:809-16. 2011
    ..A relatively simple adjustment of conventional FRAX estimates of probabilities of hip fracture and a major osteoporotic fracture can be applied to modulate the risk assessment with knowledge of the dose of glucocorticoids...
  19. ncbi request reprint A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, UK
    Bone 47:729-35. 2010
    ..There was no significant effect on non-vertebral fracture...
  20. doi request reprint FRAX(®) with and without bone mineral density
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Calcif Tissue Int 90:1-13. 2012
    ....
  21. ncbi request reprint Development and use of FRAX in osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 21:S407-13. 2010
    ..The FRAX tool integrates information on fracture risk from clinical risk factors with or without the use of BMD and can be used to improve the targeting of individuals at high fracture risk...
  22. ncbi request reprint How to decide who to treat
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK
    Best Pract Res Clin Rheumatol 23:711-26. 2009
    ..The tool increases sensitivity without trading specificity and is now being used in the re-appraisal of clinical guidelines...
  23. doi request reprint Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX
    John A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
    Bone 44:1049-54. 2009
    ..No significant effect was noted on the risk of clinical fractures, but fracture risk reduction was reported in a post hoc subgroup analysis in a high risk group categorised on the basis of BMD and prior fracture...
  24. doi request reprint The effects of a FRAX revision for the USA
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 21:35-40. 2010
    ..With the revised tool, there were strong correlations (r > 0.99) between versions 2.0 and 3.0 for FRAX estimates of fracture probability, but the revised models gave lower probability estimates...
  25. pmc FRAX and the assessment of fracture probability in men and women from the UK
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 19:385-97. 2008
    ..A fracture risk assessment tool (FRAX) is developed based on the use of clinical risk factors with or without bone mineral density tests applied to the UK...
  26. pmc European guidance for the diagnosis and management of osteoporosis in postmenopausal women
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 19:399-428. 2008
    ..Guidance is provided in a European setting on the assessment and treatment of postmenopausal women with or at risk from osteoporosis...
  27. pmc Osteoporosis in the European Union: a compendium of country-specific reports
    A Svedbom
    OptumInsight, Stockholm, Sweden
    Arch Osteoporos 8:137. 2013
    ..This report describes epidemiology, burden, and treatment of osteoporosis in each of the 27 countries of the European Union (EU27)...
  28. ncbi request reprint A family history of fracture and fracture risk: a meta-analysis
    J A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
    Bone 35:1029-37. 2004
    ..Its identification on an international basis supports the use of this risk factor in case-finding strategies...
  29. ncbi request reprint Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial
    O Strom
    European Health Economics, Vasagaatn 38 2 tr, SE 111 20, Stockholm, Sweden
    Osteoporos Int 18:1047-61. 2007
    ..Cost-effectiveness of treatment was assessed in nine European countries in a Markov model and was generally found to be cost effective in women with a previous spine fracture...
  30. doi request reprint The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis
    F Borgstrom
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Osteoporos Int 21:339-49. 2010
    ..At a willingness-to-pay of pound 30,000 per quality-adjusted life-year (QALY), strontium ranelate was generally cost-effective in women with prior fracture at the threshold of osteoporosis from an age of 65 years...
  31. doi request reprint Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study
    E V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Osteoporos Int 20:811-7. 2009
    ..This study demonstrates that the estimation of an individual's 10-year probability of fracture by the FRAX algorithm identifies patients at high risk of fracture who will respond to bisphosphonate therapy...
  32. ncbi request reprint Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
    Osteoporos Int 12:989-95. 2001
    ..Intervention thresholds based on hip BMD T-scores are similar between sexes...
  33. ncbi request reprint The burden of osteoporotic fractures: a method for setting intervention thresholds
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 12:417-27. 2001
    ....
  34. ncbi request reprint A new approach to the development of assessment guidelines for osteoporosis
    J A Kanis
    WHO Centre for Metabolic Bone Diseases, University of Sheffield, UK
    Osteoporos Int 13:527-36. 2002
  35. ncbi request reprint Cost-effectiveness of preventing hip fracture in the general female population
    J A Kanis
    Centre for Metabolic Bone Diseases (WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 12:356-61. 2001
    ..We conclude that segments of the apparently healthy population could be advantaged by treatment if efficacy were supported by randomized controlled studies...
  36. ncbi request reprint The risk and burden of vertebral fractures in Sweden
    J A Kanis
    Centre for Metabolic Bone Diseases, WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 15:20-6. 2004
    ..We conclude that vertebral fractures have a major personal and societal impact that needs to be recognised in algorithms for assessment of risk and in health economic strategies for osteoporosis...
  37. doi request reprint The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX
    F Borgstrom
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Osteoporos Int 21:495-505. 2010
    ..A Markov cohort model was used to estimate the cost-effectiveness. Risedronate was found cost-effective from the age of 65 years, assuming a willingness to pay for a QALY of 30,000 pounds...
  38. doi request reprint FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example
    O Strom
    i3 Innovus, Stockholm, Sweden
    Bone 47:430-7. 2010
    ..The objective was to describe the implementation of the FRAX algorithms into health economic osteoporosis models and to highlight how it differs from traditional risk assessment...
  39. doi request reprint Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate
    K Kayan
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 20:2055-61. 2009
    ..Fall risk does not significantly impact on the efficacy of the bisphosphonate clodronate in reducing the incidence of fracture...
  40. ncbi request reprint Diagnosis of osteoporosis and fracture threshold in men
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
    Calcif Tissue Int 69:218-21. 2001
    ..Although data are limited, prior fragility fractures increase subsequent fracture risks in both men and women. These studies suggest that the same BMD criteria used to diagnose osteoporosis in women can be applied to men...
  41. doi request reprint Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective
    F Borgstrom
    i3 Innovus, Stockholm, Sweden
    Osteoporos Int 22:955-65. 2011
    ..Cost/QALY differences were explained to a large extent by differences in fracture risk...
  42. ncbi request reprint The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture
    F Borgstrom
    LIME MMC, Karolinska Institutet, Stockholm, Sweden
    Osteoporos Int 24:811-23. 2013
    ..Analysis showed that there were significant differences in the quality of life (QoL) loss between countries. Other factors such as QoL prior fracture and hospitalisation also had a significant impact on the QoL loss...
  43. pmc SCOPE: a scorecard for osteoporosis in Europe
    J A Kanis
    University of Sheffield Medical School, Sheffield, UK
    Arch Osteoporos 8:144. 2013
    ..The resulting scorecard elements were then assembled on a single sheet to provide a unique overview of osteoporosis in Europe...
  44. pmc A high incidence of vertebral fracture in women with breast cancer
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
    Br J Cancer 79:1179-81. 1999
    ..3-9.9], and 20-fold higher in women with soft-tissue metastases without evidence of skeletal metastases (OR, 22.7; 95% CI, 9.1-57.1). We conclude that vertebral fracture risk is markedly increased in women with breast cancer...
  45. doi request reprint Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis
    O Strom
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Osteoporos Int 24:1491-502. 2013
    ..Denosumab was cost-effective in women with a risk of major osteoporotic fracture meeting or exceeding approximately 20% who are unable to take, comply with or tolerate generic alendronate...
  46. ncbi request reprint At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis
    F Borgstrom
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Osteoporos Int 17:1459-71. 2006
    ..Intervention thresholds (ITs), the 10-year hip fracture risk at which treatment can be considered to be cost-effective, have previously been estimated for Sweden and the UK...
  47. ncbi request reprint The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective
    F Borgstrom
    Stockholm Health Economics, Klarabergsgatan 333tr, SE 111 21, Stockholm, Sweden
    Osteoporos Int 17:996-1007. 2006
    ....
  48. ncbi request reprint Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture
    J A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 16:475-82. 2005
    ....
  49. ncbi request reprint Epidemiology of osteoporosis and fracture in men
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Rd, Sheffield, United Kingdom S10 2RX
    Calcif Tissue Int 75:90-9. 2004
  50. ncbi request reprint Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 24:2763-4. 2013
    ....
  51. pmc European guidance for the diagnosis and management of osteoporosis in postmenopausal women
    J A Kanis
    WHO Collaborating Centre, UK University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 24:23-57. 2013
    ..Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis...
  52. ncbi request reprint Pitfalls in the external validation of FRAX
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 23:423-31. 2012
    ..Recent studies have evaluated the performance of FRAX® in independent cohorts. The interpretation of most is problematic for reasons summarised in this perspective...
  53. ncbi request reprint BMD, clinical risk factors and their combination for hip fracture prevention
    H Johansson
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 20:1675-82. 2009
    ....
  54. ncbi request reprint The components of excess mortality after hip fracture
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Bone 32:468-73. 2003
    ..Hip fracture was a more common cause for mortality than pancreatic or stomach cancer. Thus, interventions that decreased hip fracture rate by, say, 50% would avoid 0.75% or more of all deaths...
  55. ncbi request reprint Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Bone 27:585-90. 2000
    ..The decrease in relative risk with age is, however, associated with an increase in absolute risk. Thus, for clinical use, the expression of absolute risks may be preferred to relative risks...
  56. ncbi request reprint Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis
    E McCloskey
    The WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Bone 28:310-5. 2001
    ..We conclude that clodronate 800 mg daily is effective in preventing bone loss, and at 1 year, there is a trend consistent with antifracture efficacy in patients with established osteoporosis regardless of causation...
  57. ncbi request reprint Interpretation and use of FRAX in clinical practice
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 22:2395-411. 2011
    ..Its use in fracture risk prediction has strengths, but also limitations of which the clinician should be aware and are the focus of this review..
  58. doi request reprint Incorporating adherence into health economic modelling of osteoporosis
    O Strom
    i3 Innovus, Vasagatan 38 2 tr, 111 20, Stockholm, Sweden
    Osteoporos Int 20:23-34. 2009
    ..Important variables were the magnitude of drug effect, drug price, and fracture-related costs...
  59. ncbi request reprint Study design in osteoporosis: a European perspective
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom
    J Bone Miner Res 18:1133-8. 2003
    ..If fracture studies are required by regulatory agencies, there is still a requirement for placebo-controlled studies, although perhaps of shorter duration than demanded at present...
  60. pmc A systematic review of hip fracture incidence and probability of fracture worldwide
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK
    Osteoporos Int 23:2239-56. 2012
    ..There was a greater than 10-fold variation in hip fracture risk and fracture probability between countries...
  61. pmc A reappraisal of generic bisphosphonates in osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Osteoporos Int 23:213-21. 2012
    ..The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they have more limited effectiveness than generally assumed...
  62. doi request reprint A FRAX® model for the assessment of fracture probability in Belgium
    H Johansson
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 22:453-61. 2011
    ..A country-specific FRAX® model was developed from the epidemiology of fracture and death in Belgium. Fracture probabilities were identified that corresponded to currently accepted reimbursement thresholds...
  63. ncbi request reprint Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Bone 30:251-8. 2002
    ..0/SD). Such gradients might be achieved with the use of multiple risk factors to identify patients at risk...
  64. doi request reprint Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican Institute of Social Security
    H Johansson
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
    Osteoporos Int 22:2359-64. 2011
    ..If the age-specific incidence of hip fracture continues, the number of hip fractures would increase by a further 46%...
  65. ncbi request reprint Intervention thresholds for osteoporosis
    J A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Sheffield, UK
    Bone 31:26-31. 2002
    ....
  66. ncbi request reprint Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK
    Health Technol Assess 11:iii-iv, ix-xi, 1-231. 2007
    ..To determine whether strategies can be devised for the assessment and treatment of glucocorticoid-induced osteoporosis (GIO)...
  67. ncbi request reprint Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
    E V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Medical School, Sheffield, UK
    Br J Haematol 113:1035-43. 2001
    ..These observations, however, require confirmation in prospective clinical trials...
  68. pmc A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy
    O P Purohit
    YCRC Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK
    Br J Cancer 72:1289-93. 1995
    ..We conclude that both agents are effective in the management of hypercalcaemia of malignancy. At the doses studied, the effects of pamidronate are more complete and longer lasting than those of clodronate...
  69. ncbi request reprint Optimal age for preventing osteoporosis after menopause depends on effects of stopping treatment
    F Caulin
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Bone 30:754-8. 2002
    ..This figure rose to 23 per 1000 at the age of 70 years. We conclude that, although uncertainty exists concerning the offset of effect of treatments, treatments should be optimally given to women without prior fractures in later life...
  70. ncbi request reprint Treatment of established osteoporosis: a systematic review and cost-utility analysis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Health Technol Assess 6:1-146. 2002
  71. pmc Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral density
    K Kayan
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
    Postgrad Med J 79:581-4. 2003
    ..A case finding strategy based on a number of established risk factors has been suggested by Royal College of Physicians' (RCP) guidelines to optimise bone densitometry referrals for assessment of osteoporosis...
  72. ncbi request reprint The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma
    E V McCloskey
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, England
    Drugs 61:1253-74. 2001
    ..It is not known whether more potent bisphosphonates will deliver greater clinical efficacy in the future...
  73. ncbi request reprint Uncertain future of trials in osteoporosis
    J A Kanis
    WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
    Osteoporos Int 13:443-9. 2002
    ..In this review we argue that, if new agents are to be developed, there is still a place for the placebo-controlled trial. A move to studies of equivalence or non-inferiority raises more problems than it resolves...
  74. pmc Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate)
    E V McCloskey
    Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, UK
    Br J Cancer 69:914-7. 1994
    ..We conclude that aminohexane bisphosphonate is an effective agent in the treatment of tumour-induced hypercalcaemia, with rapid onset of effect and low toxicity...
  75. ncbi request reprint Rationale for the use of bisphosphonates in breast cancer
    J A Kanis
    Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, UK
    Acta Oncol 35:61-7. 1996
    ..Given, however, the unchanging survival in patients with metastatic bone disease, significant improvements in the quality of remaining life is an important therapeutic effect...
  76. ncbi request reprint Assessing the risk of vertebral osteoporosis
    J A Kanis
    Centre for Metabolic Bone Diseases WHO Collaborating Centre, University of Sheffield Medical School, UK
    Singapore Med J 43:100-5. 2002
    ..The impact of BMD, age and other risks on fracture probability have recently been determined and provide a mechanism for optimising assessment of patients so that treatments can be efficiently directed to those most in need...
  77. ncbi request reprint Atypical familial Paget's disease of bone
    K C Pande
    WHO Collaborating Centre for Metabolic Bone Diseases, Royal Hallamshire Hospital, Sheffield, UK
    Joint Bone Spine 68:257-61. 2001
    ..We report unusual clinical and radiological features of Paget's disease of bone in three family members. All three patients had satisfactory biochemical and symptomatic response to treatment with an intravenous bisphosphonate (clodronate)...
  78. pmc Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate
    E V McCloskey
    Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, UK
    Br J Cancer 67:560-3. 1993
    ..The single infusion has a more rapid onset of effect, is more convenient than multiple infusions, and has no adverse effect on renal function...